Lineage Cell Therapeutics (LCTX) Intangibles (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Intangibles of $31.7 million for Q1 2026, little changed quarter-over-quarter from $31.7 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Intangibles (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Intangibles history runs 17 years deep, the most recent figure standing at $31.7 million for Q1 2026.
- In Q1 2026, Intangibles changed N/A year-over-year to $31.7 million; the TTM figure through Mar 2026 stood at $31.7 million (changed N/A YoY), while the FY2025 annual figure was $31.7 million, down 31.89% from the prior year.
- Intangibles for Q1 2026 stood at $31.7 million, roughly flat from $31.7 million in the prior quarter.
- The five-year high for Intangibles was $66.1 million in Q4 2022, with the low at $31.7 million in Q3 2025.
- The 5-year median for Intangibles is $46.6 million (2023), against an average of $51.4 million.
- The sharpest annual moves came in 2022 and 2025: Intangibles soared 213.34% in 2022, then tumbled 52.07% in 2025.
- Lineage Cell Therapeutics' Intangibles stood at $66.1 million in 2022, then declined by 29.6% to $46.6 million in 2023, then fell by 0.05% to $46.5 million in 2024, then slumped by 31.89% to $31.7 million in 2025, then changed by 0.0% to $31.7 million in 2026.
- Business Quant data shows LCTX's Intangibles at $31.7 million in Q1 2026, $31.7 million in Q4 2025, and $31.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 31.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.70 Mn |
| Mar 31, 2026 | 31.70 Mn |
| Dec 31, 2025 | 31.70 Mn |
| Sep 30, 2025 | 31.70 Mn |
| Dec 31, 2024 | 46.54 Mn |
| Sep 30, 2024 | 66.14 Mn |
| Jun 30, 2024 | 66.14 Mn |
| Mar 31, 2024 | 66.14 Mn |
| Dec 31, 2023 | 46.56 Mn |
| Sep 30, 2023 | 66.14 Mn |
| Jun 30, 2023 | 46.63 Mn |
| Mar 31, 2023 | 66.14 Mn |
| Dec 31, 2022 | 66.14 Mn |
| Sep 30, 2022 | 46.50 Mn |
| Jun 30, 2022 | 46.50 Mn |
| Mar 31, 2022 | 46.50 Mn |
| Dec 31, 2021 | 46.82 Mn |
| Sep 30, 2021 | 66.14 Mn |
| Jun 30, 2021 | 46.89 Mn |
| Mar 31, 2021 | 14.84 Mn |